The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ:SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results